Anaemia is a common complication of chemotherapy. Since anaemia can lead to different symptoms, such as fatigue, respiratory distress and chest pain, thereby diminishing physical capacity and quality of life, it is generally accepted that anaemia should be corrected. Treatment options include red blood cell transfusion (RBCT), erythropoietin (EPO) administration or a combination of both. OBJECTIVE: Our objective was to carry out a cost-effectiveness analysis of treatment with EPO (erythropoietin alpha) compared to traditional treatment with RBCT for patients with chemotherapy-induced anaemia in Sweden from a hospital perspective. METHOD: We developed a model for Swedish treatment practice (patient characteristics, response rates, and RBC transfusion data taken from Swedish observational data), and Swedish unit costs, based on a model commissioned by the National Institute of Clinical Excellence, UK. Incremental costs associated with EPO treatment compared to treatment with RBCT, were estimated. Different cancer types and populations were modelled by varying initial Hb, response and mortality rates. RESULTS: The model results on costs correspond well to real world data from three big hospitals in Sweden. Average costs per patient are SEK34,900 for EPO and SEK 12,400 for RBCT. The cost per QALY gained from administration of EPO assuming a survival benefit attributable to EPO treatment was estimated at SEK 120,000. The survival benefit from EPO is debated, and has a major impact of the results. Excluding this benefit gives an estimated cost of SEK 365,000 per QALY. EPO treatment is most cost-effective in patients with initial Hb of 9-10 g/dl. The cost-effectiveness-ratio is also moderately sensitive to changes in the response rate to EPO, baseline mortality, the cost of EPO and the estimated QALY gain from EPO administration. CONCLUSION: The estimated cost per QALY falls well within the range acceptable in Sweden. The cost-effectiveness of EPO varies between different cancer populations. International Health Policy Program-Thailand, Nonthaburi, Thailand, 2 National Health Foundation, Bangkok, Thailand OBJECTIVES: To describe factors influencing inequitable access to radiation therapy among cancer patients in Thailand by exploring the current situation and problems of both demand and supply sides after implementation of the policy on universal coverage. The study aimed to improve efficiency in health resource allocation and equitable access to expensive health services by using radiation therapy as the case study. METHODS:
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METHODS:
The UK National Health Service (NHS) recently announced a bowel cancer screening programme consisting of biennial faecal occult blood testing (FOBT) to be phased in starting April 2006 (25% of the potential population screened in years 1 and 2 and 50% in year 3). Selection of this screening strategy was based on an independent economic evaluation (Tappenden 2004) that ranked it fourth out of five alternative strategies in terms of cost effectiveness. We fitted a Bayesian autoregressive age-period-cohort model to data of bowel cancer incidence in the UK 1993-2004/5 to estimate the cost savings and impact on outcomes resulting from phased implementation, and from choosing a less expensive, less cost-effective screening programme. UK costings were derived from the previous Tappenden 2004 analysis. RESULTS: We estimate that in the period 2006-2009, phased implementation of the chosen biennial FOBT programme will save GBP146 million compared to full implementation, but will also result in 2440 fewer bowel cancer cases detected. Adoption of the most cost-effective screening strategy would increase the number of cancers detected by 737, and would cost GBP1.49 million less to implement than the chosen option at the governmental phased rates in this three-year period. When compared to no screening, it costs GBP23,679 to detect a bowel cancer case using biennial FOBT in the age group 60-69. In the same age group, using the more cost effective strategy of FSIG plus biennial FOBT it costs GBP18,534 to detect a bowel cancer case. CONCLUSION: Affordability and service impact appeared to be more important factors than cost effectiveness in selecting a bowel cancer-screening program for the UK.
PCN51 PHYSICIAN AND PATIENT CHARACTERISTICS ASSOCIATED WITH OUTPATIENT BREAST CANCER SCREENING RECOMMENDATIONS: ANALYSIS OF US OUTPATIENT DATA 1996-2004
Balkrishnan R, Bhosle MJ The Ohio State University College of Pharmacy, Columbus, OH, USA OBJECTIVE: The primary goal of breast cancer screening tests is to find cancer at an early stage before a person has any symptoms. Evidence suggests that screening examinations such as mammography and clinical breast examinations (CBE) are effective in early detection of breast cancer. Physician recommendation is an important reason many women undergo screening. This study examined the physician and patients related factors associated with physician recommendations for breast cancer screening in the United States (US) outpatient settings. METHODS: This cross-sectional study used data from the National Ambulatory Medical Care Survey (NACMS) from 1996¨C2004. Women aged °Ý 40 years were included in the study sample. Multivariate logistic regression analyses were used to study the objectives. RESULTS: Weighted analysis indicated that physicians performed 198 million CBEs and made 110 million mammography recommendations over the study period (1996) (1997) (1998) (1999) (2000) (2001) (2002) (2003) (2004) . Patients' age, duration of visits, history of previous breast cancer diagnosis, and source of insurance were significant predictors of screening recommendations in this population. Obstetricians and gynecologists were more likely to perform a CBE and recommend mammography than other specialty physicians. CONCLUSIONS: These findings indicated that there were certain disparities regarding the physician recommendations of breast cancer screening for women in the US outpatient settings. 
